Pfizer expands Cambridge Kendall Square research facility
Pfizer has expanded its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus.With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main St. in Kendall Square in Cambridge, Mass. This space will continue to house the R&D activities that relocated to the building in 2014, and will enable the consolidation of Pfizer’s three other leased spaces in Cambridge into the one campus.
This most recent lease addition secures an added 130,000 square feet of space for potential expansion in the future and will be available for sub-tenancy in 2017. Once the three remote sites are consolidated, 610 Main St. will house approximately 1,000 Pfizer employees.
Pfizer’s R&D efforts in Cambridge will continue to focus on rare diseases, cardiovascular and metabolic disease, inflammation and immunology, neuroscience and advanced biotherapeutic technologies.